Your browser doesn't support javascript.
loading
Prevalence and phenotype associations of complement factor I mutations in geographic atrophy.
Khan, Adnan H; Sutton, Janice; Cree, Angela J; Khandhadia, Samir; De Salvo, Gabriella; Tobin, John; Prakash, Priya; Arora, Rashi; Amoaku, Winfried; Charbel Issa, Peter; MacLaren, Robert E; Bishop, Paul N; Peto, Tunde; Mohamed, Quresh; Steel, David H; Sivaprasad, Sobha; Bailey, Clare; Menon, Geeta; Kavanagh, David; Lotery, Andrew J.
Afiliação
  • Khan AH; Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Sutton J; Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Cree AJ; Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Khandhadia S; Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • De Salvo G; Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Tobin J; Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Prakash P; Gyroscope Therapeutics Limited, Stevenage, UK.
  • Arora R; The Eye Unit, The Princess Alexandra Hospital NHS Trust, Harlow, UK.
  • Amoaku W; Department of Ophthalmology, Salisbury District Hospital, Salisbury NHS Foundation Trust, Salisbury, UK.
  • Charbel Issa P; Eye and ENT Centre, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • MacLaren RE; Oxford Eye Hospital and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Bishop PN; Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Peto T; Oxford Eye Hospital and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Mohamed Q; Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Steel DH; Division of Evolution and Genomic Sciences, Faculty of Medicine and Health, School of Biological Sciences, University of Manchester, Manchester, UK.
  • Sivaprasad S; Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Bailey C; Centre for Public Health, School of Medicine, Institute of Clinical Sciences, Queen's University Belfast, Belfast, UK.
  • Menon G; Department of Ophthalmology, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
  • Kavanagh D; Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
  • Lotery AJ; Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Hum Mutat ; 42(9): 1139-1152, 2021 09.
Article em En | MEDLINE | ID: mdl-34153144
ABSTRACT
Rare variants in the complement factor I (CFI) gene, associated with low serum factor I (FI) levels, are strong risk factors for developing the advanced stages of age-related macular degeneration (AMD). No studies have been undertaken on the prevalence of disease-causing CFI mutations in patients with geographic atrophy (GA) secondary to AMD. A multicenter, cross-sectional, noninterventional study was undertaken to identify the prevalence of pathogenic rare CFI gene variants in an unselected cohort of patients with GA and low FI levels. A genotype-phenotype study was performed. Four hundred and sixty-eight patients with GA secondary to AMD were recruited to the study, and 19.4% (n = 91) demonstrated a low serum FI concentration (below 15.6 µg/ml). CFI gene sequencing on these patients resulted in the detection of rare CFI variants in 4.7% (n = 22) of recruited patients. The prevalence of CFI variants in patients with low serum FI levels and GA was 25%. Of the total patients recruited, 3.2% (n = 15) expressed a CFI variant classified as pathogenic or likely pathogenic. The presence of reticular pseudodrusen was detected in all patients with pathogenic CFI gene variants. Patients with pathogenic CFI gene variants and low serum FI levels might be suitable for FI supplementation in therapeutic trials.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator I do Complemento / Atrofia Geográfica Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Hum Mutat Assunto da revista: GENETICA MEDICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator I do Complemento / Atrofia Geográfica Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Hum Mutat Assunto da revista: GENETICA MEDICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido